Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, has received notice of delisting from Nasdaq due to non-compliance with the minimum stockholder's equity requirement. The company's common stock will be suspended from trading on Nasdaq effective October 16, 2024, and is expected to begin trading on the OTCQB on the same date.
The Nasdaq Hearings Panel had previously given Seelos until October 11, 2024, to regain compliance with the Equity Standard Rule. However, the company failed to meet this requirement. Seelos cautions that there is no assurance that a broker will continue to make a market in the company's common stock or that trading will continue on an over-the-counter market or elsewhere.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
3
Translate
Report
2987 Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2479Followers
107Following
27KVisitors
Follow